|本期目录/Table of Contents|

[1]陆璐 综述,张洁,阎昭 审校.阿哌沙班治疗肿瘤相关性血栓栓塞的获益与风险[J].天津医科大学学报,2021,27(03):322-324.
点击复制

阿哌沙班治疗肿瘤相关性血栓栓塞的获益与风险(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
27卷
期数:
2021年03期
页码:
322-324
栏目:
综述
出版日期:
2021-05-30

文章信息/Info

Title:
-
文章编号:
1006-8147(2021)03-0322-04
作者:
陆璐1 综述; 张洁1; 阎昭2 审校
天津医科大学肿瘤医院1.药学部；2.临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060
Author(s):
-
关键词:
阿哌沙班; 肿瘤相关血栓; 静脉血栓栓塞症; 风险; 获益
Keywords:
-
分类号:
R97
DOI:
-
文献标志码:
A
摘要:
肿瘤相关性血栓栓塞发病率较高，并为肿瘤患者主要致死原因之一。Ⅹa因子抑制剂阿哌沙班比低分子肝素治疗方案具有一定的临床应用优势。现有研究证据表明，其对肿瘤相关血栓的长期预防可能获益，但也可能存在一定的风险。在阐述肿瘤相关血栓病理学特点的基础上，分析阿哌沙班用于预防或治疗肿瘤相关血栓栓塞疗效与安全性研究的各类证据，可多维度评估其对肿瘤相关血栓栓塞的获益与风险，为临床合理用药提供依据。
Abstract:
-

参考文献/References:

[1] Cohen A T，Katholing A，Rietbrock S，et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: a population-based cohort study[J]. Thromb Haemost，2017，117（1）：57
[2] Khorana A A，Francis C W，Culakova E，et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J]. Thromb Haemost，2007，5（3）：632
[3] Prandoni P，Lensing A W，Piccioli A，et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis[J]. Blood，2002， 100（10）：3484
[4] Farge D，Frere C，Connors J M，et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. Lancet Oncol，2019，20（10）：e566
[5] Khorana A A，Carrier M，Garcia D A，et al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism[J]. Thromb Thrombolysis，2016，41（1）：81
[6] Ay C，Pabinger I，Cohen A T. Cancer-associated venous thromboembolism：burden，mechanisms，and management[J].Thromb Haemost，2017，117（2）：219
[7] Rojas-Hernandez C M. The role of direct oral anticoagulants in cancer-related venous thromboembolism：a perspective beyond the guidelines[J]. Support Care Cancer，2018，26（3）：711
[8] Mahé I，Elalamy I，Gerotziafas G T，et al. Treatment of cancer- associated thrombosis：beyond HOKUSAI[J].TH Open，2019，3（3）：e348
[9] Raskob G E，van Es N，Verhamme P，et al. Edoxaban for the treatment of cancer-associated venous thromboembolism[J]. N Engl J Med，2018，378（7）：615
[10] Young A M，Marshall A，Thirlwall J，et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism：results of a randomized trial （SELECT-D）[J]. Clin Oncol，2018，36（20）：2017
[11] Agnelli G，Buller H R，Cohen A，et al. Oral apixaban for the treatment of acute venous Thromboembolism[J]. N Engl J Med，2013， 369（9）：799
[12] Blom J W，Doggen C J，Osanto S，et al. Malignancies，prothrombotic mutations，and the risk of venous thrombosis[J]. JAMA，2005， 293（6）：715
[13] Timp J F，Braekkan S K，Versteeg H H，et al. Epidemiology of cancer-associated venous thrombosis[J]. Blood，2013，122（10）：1712
[14] Khorana A A，Kuderer N M，Culakova E，et al. Development and validation of a predictive model for chemotherapy-associated thrombosis[J]. Blood，2008，111（10）：4902
[15] Chew H K，Wun T，Harvey D，et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J]. Arch Intern Med，2006，166（4）：458
[16] Donnelan E，Kevane B，Bird B R，et al. Cancer and venous thromboembolic disease： from molecular mechanisms to clinical management[J]. Curr Oncol，2014，21（3）：134
[17] Geddings J E，Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients[J]. Blood，2013，122（11）：1873
[18] Tesselaar M E，Romijn F P，Linden I K，et al. Microparticle-associated tissue factor activity：a link between cancer and thrombosis[J]. Thromb Haemost，2007，5（3）：520
[19] Menter D G，Tucker S C，Kopetz S，et al. Platelets and cancer： a casual or causal relationship：revisited[J]. Cancer Metastasis Rev，2014，33（1）：231
[20] Wong P C，Jiang X. Apixaban，a direct factor Xa inhibitor，inhibits tissue-factor induced human platelet aggregation in vitro：comparison with direct inhibitors of factor Ⅶa，Ⅺa and thrombin[J]. Thromb Haemost，2010，104（2）：302
[21] Byon W，Garonzik S，Boyd R A，et al. Apixaban：a clinical pharmacokinetic and pharmacodynamic review[J]. Clin Pharmacokinet，2019，58（10）：1265
[22] Agnelli G，Buller H R，Cohen A，et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients： results from the AMPLIFY trial[J]. Thromb Haemost，2015，13（12）：2187
[23] McBaneli R，Loprinzi C L，Ashrani A，et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial[J]. Thromb Haemost，2017，117（10）：1952
[24] Agnelli G，Becattini C，Meyer G，et al. Apixaban for the treatment of venous thromboembolism associated with cancer[J]. N Engl J Med，2020，382（17）：1599
[25] McBane R D，Loprinzi C L，AshraniA，et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients： the EVE trial[J]. Eur J Haematol，2020，104（2），88
[26] Stubblefield W B，Courtney D M，Self W H. Should cancer patients receive apixaban to prevent venous thromboembolism? An analysis of the AVERT trial[J]. Ann Emerg Med，2020，75（1）：116
[27] Shaw J R，Kumar V，Mallick R，et al. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer[J]. Thromb Res，2020， 10（196），437
[28] Dawwas G K，Brown J，Dietrich E，et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism： a retrospective population-based cohort analysis[J]. Lancet Haematol，2019，6（1）：e20
[29] Li A，Kuderer N M，Garcia D A，et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer： asystematic review and meta-analysis[J]. J Thromb Haemost，2019， 17（12）：2141

相似文献/References:

备注/Memo

备注/Memo:
作者简介 陆璐（1989-），女，主管药师，硕士在读，研究方向：临床药学；
通信作者：阎昭， E-mail：yanzhaopaper@163.com。
更新日期/Last Update: 2021-05-30